menu
    • menu
    [{"orgOrder":0,"company":"MERCK CANADA INC","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"MERCK CANADA INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MERCK CANADA INC \/ MERCK CANADA INC","highestDevelopmentStatusID":"11","companyTruncated":"MERCK CANADA INC \/ MERCK CANADA INC"},{"orgOrder":0,"company":"MERCK CANADA INC","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rocuronium Bromide","moa":"Muscle-type nicotinic acetylcholine receptor","graph1":"Undisclosed","graph2":"Phase IV","graph3":"MERCK CANADA INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MERCK CANADA INC \/ MERCK CANADA INC","highestDevelopmentStatusID":"11","companyTruncated":"MERCK CANADA INC \/ MERCK CANADA INC"},{"orgOrder":0,"company":"MERCK CANADA INC","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium | Vecuronium","graph1":"Sleep","graph2":"Phase IV","graph3":"MERCK CANADA INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MERCK CANADA INC \/ MERCK CANADA INC","highestDevelopmentStatusID":"11","companyTruncated":"MERCK CANADA INC \/ MERCK CANADA INC"},{"orgOrder":0,"company":"MERCK CANADA INC","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"MERCK CANADA INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MERCK CANADA INC \/ MERCK CANADA INC","highestDevelopmentStatusID":"1","companyTruncated":"MERCK CANADA INC \/ MERCK CANADA INC"},{"orgOrder":0,"company":"MERCK CANADA INC","sponsor":"MERCK CANADA INC","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"MERCK CANADA INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"MERCK CANADA INC \/ MERCK CANADA INC","highestDevelopmentStatusID":"11","companyTruncated":"MERCK CANADA INC \/ MERCK CANADA INC"}]

    Find Clinical Drug Pipeline Developments & Deals by MERCK CANADA INC

    Menu

    MERCK CANADA INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HPV Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Queen's University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with H...

                            Details : HPV Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of Uterine Cervical Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 07, 2024

                            Lead Product(s) : HPV Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Queen's University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doravirine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

                            Details : Doravirine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Doravirine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rocuronium Bromide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : CIUSSS de l'Est-de-l'Île-de-Montréal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Intraoperative Deep Neuromuscular Blockade on NOL-guided Opioid Requirement in LSC Colorectal Surger...

                            Details : Rocuronium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2019

                            Lead Product(s) : Rocuronium Bromide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : CIUSSS de l'Est-de-l'Île-de-Montréal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Sleep

                            Study Phase : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

                            Details : Sugammadex sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Sleep Apnea, Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2018

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase IV

                            Recipient : University Health Network, Toronto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            MERCK CANADA INC

                            Canada arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Recipient : University of British Columbia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine

                            Details : Human Papillomavirus 9-valent Vaccine, Recombinant is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 18, 2016

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Recipient : University of British Columbia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth